Your browser doesn't support javascript.
loading
Autologous peripheral blood stem cell mobilization following dose-adjusted cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy alone or in combination with rituximab in treating high-risk non-Hodgkin's lymphoma.
Shi, Yuankai; Zhou, Ping; Han, Xiaohong; He, Xiaohui; Zhou, Shengyu; Liu, Peng; Yang, Jianliang; Zhang, Changgong; Gui, Lin; Qin, Yan; Yang, Sheng; Zhao, Liya; Yao, Jiarui; Zhang, Shuxiang.
Affiliation
  • Shi Y; Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, 100021, P. R. China. syuankai@cicams.ac.cn.
  • Zhou P; Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, 100021, P. R. China. Zhouping_1989@sina.cn.
  • Han X; Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, 100021, P. R. China. xiaohonghan@hotmail.com.
  • He X; Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, 100021, P. R. China. xiaohuih2008@163.com.
  • Zhou S; Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, 100021, P. R. China. typhoonwho@hotmail.com.
  • Liu P; Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, 100021, P. R. China. 13910216310@163.com.
  • Yang J; Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, 100021, P. R. China. yjianl@yahoo.com.cn.
  • Zhang C; Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, 100021, P. R. China. zhchg1974@sohu.com.
  • Gui L; Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, 100021, P. R. China. guilindoctor@126.com.
  • Qin Y; Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, 100021, P. R. China. qinyan66@vip.sina.com.
  • Yang S; Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, 100021, P. R. China. medart@126.com.
  • Zhao L; Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, 100021, P. R. China. zhaoliya620125@sohu.com.
  • Yao J; Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, 100021, P. R. China. carrieyao531@hotmail.com.
  • Zhang S; Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, 100021, P. R. China. suthywg@sina.com.
Chin J Cancer ; 34(11): 522-30, 2015 Sep 14.
Article in En | MEDLINE | ID: mdl-26370464
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lymphoma, Non-Hodgkin / Antineoplastic Combined Chemotherapy Protocols / Hematopoietic Stem Cell Mobilization / Rituximab Type of study: Etiology_studies / Observational_studies / Risk_factors_studies Limits: Humans Language: En Journal: Chin J Cancer Journal subject: NEOPLASIAS Year: 2015 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lymphoma, Non-Hodgkin / Antineoplastic Combined Chemotherapy Protocols / Hematopoietic Stem Cell Mobilization / Rituximab Type of study: Etiology_studies / Observational_studies / Risk_factors_studies Limits: Humans Language: En Journal: Chin J Cancer Journal subject: NEOPLASIAS Year: 2015 Type: Article